You are here: Home > Institute of Excellence (CPD) > CPD Events > What’s New? What’s Best? Dry Eye Drops, Demodex, MGD, DEWSIII Update & More!

What’s New? What’s Best? Dry Eye Drops, Demodex, MGD, DEWSIII Update & More!

Date: 15/07/2025 ()

Venue: https://cvent.me/MMn33L, AUSTRALIA

Provider: Cornea & Contact Lens Society of Australia

Contact: CORP COMM, [E] info@corpcomm.com.au, [P] 03 5977 0244

Activity Outline

What’s New? What’s Best?

Dry Eye Drops, Demodex, MGD, DEWSIII Update & More!

Picking the Best Options for Patients

New Dry Eye Management Options


Long-Term Management

Managing expectations

Ethics & Economics

Sponsor Presentations

Panel, Q&A & Discussion

Cornea and Contact Lens Society of Australia (CCLSA)

Tuesday 15th JULY 2025

7:30PM to 9:00PM AEST

Learning Objectives

  • Understand how DEWS III has changed how we understand and look at dry eye from DEWS II
  • Understand the evolving pathophysiology of dry eye - with a first time look at neurosensory dysregulation and its role in dry eye.
  • Identify the types of dry eye and identify which patients may benefit from an eye drop that supports multiple layers of the tear film
  • Describe the unique mechanism of action of novel new moisturising drops to enter the Australian market such as ROHTO Dry Aid, and clinical indications and its role in symptom modulation and its potential place in a prescribing hierarchy for prescribing for dry eye
  • Understand the core values and missions of ROHTO and know of upcoming products
  • Understand options to control or eliminate Demodex and understand what does not eliminate Demodex
  • Understand the benefits of clean eyelids and lashes
  • Understand that providing options to patients is critical and recognise the available options
  • Apply clinical reasoning through real-world case discussions involving ROHTO

Max CPD hours awarded: 1.5

Session Information

Name
Not Just another Dry Eye Drop!
Clinical?
Yes
Interactive?
No
Therapeutic?
Yes
Duration of CPD Session/Module
0.5
Duration of CPD Session/Module inclusive of Assessment Component
0.5
Name
Sponsor Message
Clinical?
No
Interactive?
No
Therapeutic?
No
Duration of CPD Session/Module
0.25
Duration of CPD Session/Module inclusive of Assessment Component
0.25
Name
Best Strategies for Managing Demodex and Blepharitis.
Clinical?
Yes
Interactive?
No
Therapeutic?
No
Duration of CPD Session/Module
0.5
Duration of CPD Session/Module inclusive of Assessment Component
0.5
Name
Panel Q&A
Clinical?
Yes
Interactive?
Yes
Therapeutic?
No
Duration of CPD Session/Module
0.25
Duration of CPD Session/Module inclusive of Assessment Component
0.25

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.